eriodictyol 7 o rutinoside  (MedChemExpress)

Journal: Journal of Translational Medicine

Article Title: Eriocitrin inhibits sodium iodate-induced cuproptosis and barrier function impairment in retinal pigment epithelium via SIRT7/YAP/ATP7A pathway

doi: 10.1186/s12967-025-07451-w

Figure Lengend Snippet: Protective effects of eriocitrin against NaIO₃-induced cytotoxicity, inflammation, and barrier impairment. ( A ) CCK-8 assay: Cell viability of ARPE-19 cells was assessed following treatment with various concentrations of eriocitrin (0, 10, 20, 40, 80, and 100 µM) for 24 h ( n = 8). ( B ) CCK-8 assays were performed after treating cells with 40 µM eriocitrin for different duration periods (0, 6, 12, 24, 48, and 72 h) ( n = 8). ( C ) Intracellular reactive oxygen species (ROS) levels ( n = 7). ( D ) ELISA was performed to determine the expression levels of inflammatory cytokines (IL-8 and IL-1β) ( n = 8). ( E ) Trans-epithelial electrical resistance (TEER) assay ( n = 5). ( F - G ) MitoSOX Red mitochondrial superoxide fluorescence image and quantitative analysis ( n = 8). ( H - I ) Western blot analysis and quantitative analysis of key cellular barrier function proteins (ZO-1, Occludin, Claudin5, JAM-A) ( n = 3). Er: eriocitrin. Er-low: 40µM of eriocitrin; Er-high: 100µM of eriocitrin. Data were normalized to β-actin. Data were presented as mean ± SD ( n ≥ 3 independent biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Eriocitrin (purity ≥ 98%, HY-N0198), ES-Cu (Copper Ionophore, HY-112906), verteporfin (HY-B0146) were obtained from MedChemExpress (MCE, USA).

Techniques: CCK-8 Assay, Enzyme-linked Immunosorbent Assay, Expressing, Fluorescence, Western Blot

Journal: Journal of Translational Medicine

Article Title: Eriocitrin inhibits sodium iodate-induced cuproptosis and barrier function impairment in retinal pigment epithelium via SIRT7/YAP/ATP7A pathway

doi: 10.1186/s12967-025-07451-w

Figure Lengend Snippet: Eriocitrin ameliorated impaired retinal barrier function and elevated oxidative stress in NaIO₃-induced mouse model. ( A ) Immunofluorescence images of RPE65. ( B ) Quantification of total retinal thickness, ONL thickness, and INL thickness ( n = 5). ( C ) ELISA analysis of RPE65 levels in retinal tissue ( n = 8). ( D ) Quantification of a-wave and b-wave amplitudes in photopic and scotopic electroretinography (ERG) respectively ( n = 5). ( E ) Quantification of ROS levels in the retina and RPE/choroid of mouse model ( n = 5). ( F ) ELISA analysis of retinal barrier-associated proteins (ZO-1, Occludin, Claudin-5, and JAM-A) ( n = 8). Er: eriocitrin. Er-low: 25 mg/kg of eriocitrin; Er-high: 50 mg/kg of eriocitrin. Scale bar: 50 μm. Data were presented as mean ± SD ( n ≥ 3 independent biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Eriocitrin (purity ≥ 98%, HY-N0198), ES-Cu (Copper Ionophore, HY-112906), verteporfin (HY-B0146) were obtained from MedChemExpress (MCE, USA).

Techniques: Immunofluorescence, Enzyme-linked Immunosorbent Assay

Journal: Journal of Translational Medicine

Article Title: Eriocitrin inhibits sodium iodate-induced cuproptosis and barrier function impairment in retinal pigment epithelium via SIRT7/YAP/ATP7A pathway

doi: 10.1186/s12967-025-07451-w

Figure Lengend Snippet: Eriocitrin restored barrier function in ARPE-19 cells by modulating cuproptosis, which can be reversed by the cuproptosis activator ES-Cu. ( A - B ) Western blot analysis and quantification of key cuproptosis-related proteins (FDX1, DLAT, ATP7A) in ARPE-19 cells ( n = 3). ( C ) Intracellular copper ion concentration analysis ( n = 7). ( D ) CCK-8 assay ( n = 8). ( E - F ) Western blot and quantification analysis of barrier function-related proteins ( n = 3). ( G - H ) MitoSOX Red mitochondrial superoxide fluorescence image and quantitative analysis ( n = 7). ( I ) TEER measurement ( n = 5). ( J ) FITC-dextran permeability assay ( n = 5). ES-Cu: cuproptosis activator. Data were normalized to β-actin. Data were presented as mean ± SD ( n ≥ 3 independent biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Eriocitrin (purity ≥ 98%, HY-N0198), ES-Cu (Copper Ionophore, HY-112906), verteporfin (HY-B0146) were obtained from MedChemExpress (MCE, USA).

Techniques: Western Blot, Concentration Assay, CCK-8 Assay, Fluorescence, FITC-Dextran Permeability Assay

Journal: Journal of Translational Medicine

Article Title: Eriocitrin inhibits sodium iodate-induced cuproptosis and barrier function impairment in retinal pigment epithelium via SIRT7/YAP/ATP7A pathway

doi: 10.1186/s12967-025-07451-w

Figure Lengend Snippet: Eriocitrin inhibited cuproptosis by targeting SIRT7 to regulate the YAP/ATP7A pathway. ( A ) qPCR analysis of cuproptosis-related gene expression ( n = 8). ( B ) WB detection of protein expression after siRNA gene silencing of SIRT7 ( n = 3). ( C - D ) WB analysis of YAP/ATP7A axis ( n = 3). ( E ) qPCR analysis of cuproptosis-related gene expression ( n = 8). ( F ) WB detection of YAP expression after addition of Verteporfin ( n = 3). ( G ) WB analysis of SIRT7, ATP7A expression ( n = 3). ( H ) WB detection of protein expression after siRNA gene silencing of ATP7A ( n = 3). ( I ) WB analysis of YAP, FDX1, DLAT ( n = 3). ( J ) WB analysis of FDX1, DLAT ( n = 3). si-RNA, siRNA negative control. Verteporfin, YAP inhibitor. Data were normalized to β-actin. Data were presented as mean ± SD ( n ≥ 3 independent biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Eriocitrin (purity ≥ 98%, HY-N0198), ES-Cu (Copper Ionophore, HY-112906), verteporfin (HY-B0146) were obtained from MedChemExpress (MCE, USA).

Techniques: Gene Expression, Expressing, Negative Control

Journal: Journal of Translational Medicine

Article Title: Eriocitrin inhibits sodium iodate-induced cuproptosis and barrier function impairment in retinal pigment epithelium via SIRT7/YAP/ATP7A pathway

doi: 10.1186/s12967-025-07451-w

Figure Lengend Snippet: SIRT7 deficiency significantly impaired the protective effect of eriocitrin in alleviating NaIO₃-induced retinal barrier dysfunction and cuproptosis. ( A - B ) Western blot analysis of SIRT7 expression in mouse retinal tissue ( n = 3). ( C ) Retinal copper ion levels ( n = 7). ( D - E ) Immunofluorescence images of RPE65 in mouse retinal tissue and quantitative analysis ( n = 5). ( F - G ) Western blot analysis and quantification of YAP, ATP7A, FDX1, and DLAT protein expression ( n = 3). ( H ) qRT-PCR analysis of cuproptosis-related genes including FDX1 and DLAT ( n = 9). ( I - J ) Western blot analysis of barrier function proteins in retinal tissues ( n = 3). Scramble group: non-specific shRNA. Er: eriocitrin. Data were normalized to β-actin. Scale bar: 50 μm. Data were presented as mean ± SD ( n ≥ 3 independent biological replicates). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Eriocitrin (purity ≥ 98%, HY-N0198), ES-Cu (Copper Ionophore, HY-112906), verteporfin (HY-B0146) were obtained from MedChemExpress (MCE, USA).

Techniques: Western Blot, Expressing, Immunofluorescence, Quantitative RT-PCR, shRNA